Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Pemetrexed (used as a platinum doublet or as a maintenance regimen) is an established therapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). In addition, certain gene rearrangements (e.g., ALK, ROS1, RET) appear to especially benefit from the use of pemetrexed. Inferior...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Tejas, Nie, Yunan, Aisner, Dara L., Camidge, David Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777186/
https://www.ncbi.nlm.nih.gov/pubmed/35070994
http://dx.doi.org/10.3389/fonc.2021.788245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777186/
https://www.ncbi.nlm.nih.gov/pubmed/35070994
http://dx.doi.org/10.3389/fonc.2021.788245

Ejemplares similares